Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 464

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 4
Chunk 464
---
 United States and/or Europe. Even if we are successful in having our therapies or products approved for
sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products will develop. We may never be
profitable.

As noted above under the heading
“Going Concern and Management’s Plans,” through June 30, 2025, we have incurred substantial losses. We will need additional
funds both in the next twelve months and beyond for (a) research and development, (b) increases in personnel, (c) the purchase of equipment,
and investment in the development and validation of our technology. The availability of any required additional funding cannot be assured.
In addition, an adverse outcome in legal or regulatory proceedings in which we are currently involved or in the future may be involved
could adversely affect our liquidity and financial position. We may raise such funds from time to time through public or private sales
of our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure to raise capital
when needed could materially adversely affect our growth plans and our financial condition and results of operations.

58

As of June 30, 2025, the Company
had $92,700 in cash and working capital of $(28,109,502) as compared to $220,467 in cash and working capital of $(28,312,274) as of June
30, 2024. The decrease in cash of $127,767 is primarily due to the cost of operations of $7,874,647, investment in equity securities of
$500,000 and repayments of finance agreement of $971,231, partially offset by funding totaling $9,354,003
related to private placements and proceeds from note payables during the period.

Equity 

On
April 8, 2025, the Company issued 15,000,000 shares of Common Stock valued at $6,058,500 pursuant to the Stock Purchase Agreement of Biosymetrics,
Inc. (see Note 10 to the Financial Statements).

On January 21, 2025, the Company
issued 250,000 shares of Common Stock to its Chief Executive Officer of Renovaro Cube valued at $177,500 (see
Note 10 to the Financial Statements).

On October 17, 2024, the Company
issued 160,000 shares of Common Stock for consulting services valued at $118,400 (see